Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr. Lal PathLabsNSE:LALPATHLAB -0.21%93 Altman Z-Score is 35.44 as of Aug. 12, 2026, which is 16% above its 10-year median of 30.57. GuruFocus rates NSE:LALPATHLAB with a GF Score™ of 93/100 and a GF Value™ of ₹1,735.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Dr. Lal PathLabs ranks better than 99.01% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 35.44 is strong.
Dr. Lal PathLabs has a Altman Z-Score of 35.44, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Dr. Lal PathLabs's Altman Z-Score or its related term are showing as below:
NSE:LALPATHLAB'
s Altman Z-Score Range Over the Past 10 Years
Min: 15.59 Med: 30.57 Max: 56.29
Current: 35.44
During the past 13 years, Dr. Lal PathLabs's highest Altman Z-Score was 56.29. The lowest was 15.59. And the median was 30.57.
Dr. Lal PathLabs (NSE:LALPATHLAB) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Dr. Lal PathLabs Altman Z-Score Related Terms
Dr. Lal PathLabs Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Dr. Lal PathLabs's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LALPATHLAB vs TMO, DHR, IDXX: Altman Z-Score Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs Altman Z-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Dr. Lal PathLabs's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.3547
+
1.4
*
0.6843
+
3.3
*
0.2356
+
0.6
*
53.9368
+
1.0
*
0.9189
=
35.44
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a Altman Z-Score of 35.44 as of Aug. 12, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Dr. Lal PathLabs and its competitors. This is 16% above median its historical median of 30.57. Over the past decade, Dr. Lal PathLabs' Altman Z-Score has ranged from 15.59 to 56.29. According to the industry distribution chart, Dr. Lal PathLabs ranks #2 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 1%.
Is Dr. Lal PathLabs' Altman Z-Score too high?
Dr. Lal PathLabs' current Altman Z-Score of 35.44 is 16% above median its 10-year median of 30.57. Over the past 10 years, this metric has ranged from a low of 15.59 to a high of 56.29. The Medical Diagnostics & Research industry median Altman Z-Score is 2.43. Dr. Lal PathLabs' value of 35.44 is 1361.4% above this industry median. Based on the distribution chart, Dr. Lal PathLabs ranks #2 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' Altman Z-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #2 out of 202 companies for Altman Z-Score. This places Dr. Lal PathLabs in the top 1% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.43. Dr. Lal PathLabs' value of 35.44 is 1361.4% above this benchmark. Historically, Dr. Lal PathLabs' own Altman Z-Score has ranged from 15.59 to 56.29 over the past decade. While the company's 10-year median is 30.57 vs. the industry median of 2.43, Dr. Lal PathLabs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Diagnostics & Research company?
The median Altman Z-Score among Medical Diagnostics & Research companies is 2.43, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr. Lal PathLabs's current Altman Z-Score of 35.44 is 1361.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Dr. Lal PathLabs and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z-Score is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Lal PathLabs's current Altman Z-Score is 35.44, which is 16% above median its own 10-year median of 30.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current Altman Z-Score is 35.44, which is 16% above median its 10-year median of 30.57 and 1361.4% above the Medical Diagnostics & Research industry median of 2.43. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current Altman Z-Score is 35.44 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
Altman Z-Score: 35.44 (16% above median its 10-year median of 30.57)
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
Industry Position: 1361.4% above the Medical Diagnostics & Research median (#2 of 202)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
